Skip to main content
Equibles
MLYS logo

MLYS · Mineralys Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track MLYS — free

Use MLYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$27.54 -1.37 (-4.74%) At close · Sep 16
Russell 2000 member Rebalance outlook locked
Market Cap
$2.56B
Shares
88.41M

Mineralys Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Mineralys Therapeutics, Inc. (MLYS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-09-09
Mineralys Therapeutics, Inc. (MLYS) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-11
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
Confident tone Pricing strategy CKD and cardiorenal opportunity beyond hypertension Commercial launch readiness
Diluted EPS
$-2.85
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Mineralys Therapeutics, Inc. (MLYS) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Mineralys Therapeutics, Inc. (MLYS) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Confident tone Unmet need in resistant hypertension Partnering and business development Clinical data package and differentiation
Diluted EPS
$-0.47
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Confident tone FDA NDA acceptance and PDUFA date EXPLORER-OSA trial results (mixed) Life-cycle and indication expansion
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript
Confident tone Lorundrostat clinical efficacy in hypertension Label-expansion indications (CKD, OSA, heart failure) NDA submission progress
Diluted EPS
$-0.52
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript
Confident tone Lorundrostat pivotal data and differentiation Lifecycle extension in CKD and OSA Pre-commercial readiness and partnering
Diluted EPS
$-0.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Call Transcript
Confident tone Pivotal Phase 3 Trial Results (Launch-HTN and Advance-HTN) Commercial Opportunity and Physician Interest Explore-CKD Trial (Chronic Kidney Disease)
Diluted EPS
$-0.79
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
Confident tone Lorundrostat Drug Profile Pivotal Trial Readouts (Advance-HTN and Launch-HTN) Explore-CKD Phase II Trial
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript
Confident tone Pivotal Advance-HTN trial Pivotal Launch-HTN trial Explore-CKD Phase II trial
Diluted EPS
$-1.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Mineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call Transcript
Confident tone Lorundrostat Pivotal Program / Hypertension FDA Alignment & Trial Design Competitive Landscape (MRAs vs ASI)
Diluted EPS
$-0.83
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Mineralys Therapeutics, Inc. (MLYS) Q1 2024 Earnings Call Transcript
Confident tone Pivotal Hypertension Trials Targeted/Precision Medicine Strategy CKD Proof-of-Concept Trial
Diluted EPS
$-0.70
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript
Confident tone Pivotal hypertension program (Advance-HTN / Launch-HTN) Explore-CKD Phase 2 trial Obesity / GLP-1 interplay and differentiation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Mineralys Therapeutics, Inc. (MLYS) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.57
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Mineralys Therapeutics, Inc. (MLYS) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.31
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Mineralys Therapeutics, Inc. (MLYS) Q1 2023 Earnings Call
Diluted EPS
$-0.51
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Mineralys Therapeutics, Inc. (MLYS) Q4 2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–18 of 18 earnings calls
Key facts CIK 1933414 CUSIP 603170101 13F (30d) 9 filings 8 filers Visit website Investor relations